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ABSTRACT
Ocular infection of Herpes Simplex Virus-I (HSV-1) causes Herpetic Stromal Keratitis
(HSK), which is a leading cause of infectious blindness. Although complex interactions
of molecular and cellular events involve in the development of HSK, it has been known
that angiogenesis is a key step for the HSK pathogenesis. Treatment of neutralizing
°

antibody against vascular endothelial growth factor (VEGF) to inhibit VEGF activity
reduced angiogenesis and HSK severity caused by infection of HSV-1 in mouse eyes. In
addition, inactivation of cytokine which induces VEGF production and angiogenesis also
reduced angiogenesis and HSK severity. Therefore, it has been proposed that VEGF or
molecules which induce VEGF production or angiogenesis can be good target molecules
for treating HSK. In this study, we investigated whether targeting VEGF or IL-1 receptor
type I (IL-lRI) using RNAi technology could reduce angiogenesis in mouse eyes.
A general introduction and overview of RNAi were provided in Part I. Results in Part
II demonstrated that intrastromal injection of VEGF short hairpin RNA (shRNA) could
reduce VEGF production and angiogenesis caused by CpG motif in mouse eyes.
Implantation of pellets containing bio-active CpG motifs following intrastromal injection
with a plasmid expressing shRNA against VEGF reduced angiogenesis and VEGF
production. Results in Part III showed that intrastromal injection of IL-lRI shRNA could
reduce angiogenesis caused by IL-1 a through reduction of VEGF production. The results
in this dissertation indicate that targeting VEGF or IL-lRI using RNAi technology can
reduce angiogenesis in mouse eyes. Additionally, these results imply that an eye is a
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suitable organ to apply RNAi technology. Thus, this· technology may help to understand
corneal biology as well as to treat corneal diseases in the near future.
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Part I
Background and overview

1

Discovery of RNA interference (RNAi)
In 1990 Richard Jorgensen attempted to make transgenic petunias with a deep purple
color by introducing a pigment-producing gene under powerful promoter. Many of the
flowers, however, showed variegated or even white pigmentation (1). This bizarre
phenomenon, which was named co-suppression because the expression of both the
transgene and the homologous endogenous gene were suppressed, was mysterious until
1998 when Andrew Fire and Crag Mello discovered RNAi, the sequence-specific gene
silencing mediated by double stranded RNA (dsRNA) (2). They showed that the presence
of dsRNA inhibited the expression of the gene which was homologous to the dsRNA in C.
elegans. Multicopy transgenes in plant can produce low levels of dsRNA. From this
discovery, now we know that dsRNA is the molecule responsible of the previously
unsolved phenomenon, co-suppression, which is also named post transcriptional gene
silencing (PTGS) in plants. From further work it was established that co-suppression in
plant and RNAi in C. elegans share a common mechanism and that the RNAi
phenomenon occurs in many other organism including Drosophila and mammals.

Mechanisms of RNAi
The results from several in vivo and in vitro experiments have elucidated the
mechanism of RNAi. Baulcomb and Hamilton discovered the first key step. In plants
undergoing co-suppression, they identified RNAs of about 25nt nucleotides in length that
matched the sequence of the gene being silenced and which were absent in non-silenced
plants (3). Further work done by Zamore et al.(4) using Drosophila embryo lysates and
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an in vitro system from S2 cells showed that dsRNA added to Drosophila embryo lysates
was processed to length of 21-23nt and homologous endogenous mRNA was cleaved.
These results revealed that in the first step, referred to as the initiation step, long dsRNA
was digested into 21-23nt small interfering RNAs (siRNAs) (5,6,7) Biochemical
experiments showed that siRNA have a 2-3nt 3' overhang, 5' phosphate and a 3'
hydroxyl group (8). This structure is the characteristic cleavage pattern for the RNase III
family of ribonucleases. Evidence has shown that cloned enzyme, Dicer, a member of the
RNase III family, cleaves dsRNA in an ATP-dependent manner to 19-21bp siRNA.
These results suggested that the enzyme responsible for cleavage of long dsRNA to make
siRNA in the initiation step was Dicer.
In the effector step, siRNAs bind to an RNA-induced silencing complex (RISC). The
siRNA is unwound, the sense strand is removed and the antisense strand remains to lead
RISC to its target homologous mRNA. Finally, the RISC promotes cleavage of the
mRNA (5, 6, 7, 9).
In plants and C. elegans, an amplification step has been proposed (5-7).
Amplification could occur through using the antisense strand of siRNA as a primer by
RNA-dependent RNA polymerase (RdRp). Therefore, more dsRNAs could be made
through this amplification step, which provieds plant cells and C. elegans with a more
effective RNAi. Mammalian cells, however, do not have an amplification step because
they lack of RdRp. Fig. 1 shows a model for the mechanism of RNAi.
Another mechanism of RNAi is transcriptional gene silencing (TGS). This TGS
accomplished via DNA methylation or heterochromatin formation by histone methylation.
This mechanism has been studied mainly in plants (10, 11). When dsRNA degradation
3

mediated PTGS occurs in plants, the genomic DNA regions homologous to dsRNA are
often found methylated at almost all the sensitive cytosine residues. This process is
generally referred to as RNA-dependent DNA methylation, which renders the
corresponding part of the genome, especially the promoter region transcriptionally silent.
The initiator of RNA-dependent DNA methylation could be either the transgene-derived
dsRNA or siRNA (10, 11). Depending on the sequence information of the dsRNA, RNA
dependent DNA methylation was found to occur in the open reading frame or at the
promoter region of the genome (12, 13). If methylation occurs only in the open reading
frame, TGS is not affected. However, RNA-dependent DNA methylation at the promoter
sequences induces TGS and is stable and heritable (14).
RNA dependent DNA methylation has been reported mainly in plants and yeast.
However, very recently, Morris et al., (15) showed that human cells also have siRNA
induced transcriptional gene silencing. Using siRNA which targets the promoter region,
they showed transcriptional silencing is associated with DNA methylation. Therefore, it
seems that TGS is an active pathway in many organisms. However, more investigation is
necessary in order to understand RNA dependant DNA methylation in human cells.
Some evidence implies that heterochromatin formation could be the other cause of
TGS by siRNA (16-18). In C.elegans, which does not have DNA methylation, some
mutations of genes involved in RNAi machinery, mut7 and rde2, derepress transgenes
which are repressed by polycomb proteins, which maintain the chromatin
heterochromatin status. In addition, it has been found that polycomb proteins MES3,
MES4, and MES6 are required for RNAi under some experimental condition (16, 17).
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Hall et al., (18) has shown that DNA repeats, which are responsible for dsRNA, are
important for heterochromatin formation using a yeast system. They inserted a 3.6kb
centromere H repeat in a euchromatin position. The insertion of the repeats induced
silencing of a linked reporter gene and methylation of histone H3-K9. From these results,
it was suggested that dsRNA could induce heterochromatin formation. Fig. 2 shows the
basic mechanisms of TGS induced by dsRNA.

Biological function of RNAi
Many plant viruses encode suppressors of PTGS that are essential for pathogenesis.
Therefore, it seems that RNAi has an important role in pathogen resistance (19, 20).
RNAi also control endogenous transposons. In C.elegans, some RNAi-deficient strains
showed increased mobility of endogenous transposons (21, 22), which was inactivated by
heterochromatin formation. Therefore RNAi may stabilize the genome by preventing
transposition.
Natural RNAi not only prevents the transposable elements from disrupting the
integrity of genomes but also is responsible for organism development. Mutations of
ego] and dicer, involved in RNAi pathway in C. elegans cause developmental defects

(23, 24). Thus, genetic e_vidence implies that a natural role of the RNAi machinery is the
control of development of the organism. In many organisms, micro-RNAs have been
identified (25). Unlike siRNA micro-RNA is not perfect dsRNA. Micro-RNAs have hair
pin structure and do not trigger mRNA degradation. Instead, micro-RNAs hybridize to
mRNAs and prevent translation. It seems that the micro-RNA regulates endogenous gene
expression negatively. In C.elegans, let-7 and lin-4 mi-RNAs have been cloned. Lin-4
5

micro-RNA inhibits endogenous lin14 and lin28 gene expression. The mutation of many
micro-RNAs result in a developmental defect and the expression of micro-RNA is
temporal. Therefore, it appears that micro-RNAs regulate development-related genes
transient! y.

Gene silencing by siRNA in mammalian cells
Since RNAi was discovered in C. elegance the RNAi technology mediated by the
introduction of long dsRNA has been used to investigate gene function in many
organisms including Arabidopsis and Drosophila. However this long dsRNA can not be
used in mammals because the introduction of dsRNA longer than 30nt induces an
interferon response (26). Interferon induces 2' -5' oligoadenylate synthase which activate
RNaseL leading to non-specific RNA degradation (27). In addition, long dsRNA activate
the protein kinase PKR, which phosporylates and inactivate the translation initiation
factor eIF2a leading to inhibition of translation. Because dsRNA smaller than 30nt do not
activate interferon responses and long dsRNA are cleaved to form 21-23nt siRNA,
Tuschl and colleagues introduced chemically synthesized siRNA into mammalian cells to
test whether siRNA could induce gene silencing without an interferon response (26).
Introduction of synthetic siRNAs induced gene silencing effectively in a sequence
specific manner. This finding has led to the widespread use of the RNAi technology to
determine unknown gene function and to degrade mRNA which causes disease in
mammalian cells

6

Types of dsRNA inducing RNAi
Long dsRNA: Long dsRNA in cells can give rise to siRNAs through digestion of the
dsRNA by Dicer. The siRNAs bind RISC and target homologous mRNA to induce
effective gene silencing. Because various siRNAs which target the same mRNA are made
from long dsRNA, defining an optimal sequence for siRNA is not necessary. Therefore,
long dsRNA is widely used in plants, C.elegans, and Drosophila. However, long dsRNA
can not be used in mammalian cells because of the interferon response.
Synthetic siRNA: Because of its convenience, chemically synthesized siRNA is
widely used to silence genes. However, the synthetic siRNAs have some limitations. First,
the silencing effect is transient. Although the duration of the silencing effect depends on
the cell types, generally the silencing effect lasts only 4-5days in mammalian cells
because of the lack of an amplification step. Therefore, if long term inhibition of gene
expression in mammalian cells is necessary, synthetic siRNAs can not be used. Second,
synthetic siRNA is not renewable. Third, some cell lines are not transfected efficiently, so
synthetic siRNA can be used only with cell lines having a high transfection efficiency.
Short hairpin RNA (shRNA): To overcome the limitations of synthetic siRNA,
plasmid or viral vectors expressing shRNA have been developed (28, 29, 30). These
systems use the pollll promoter that produces short RNA species such as transfer RNA
and 5s RNA which are not translated into protein. Two polill promoters have been used
predominantly, the U6 promoter and Hl promoter. Many researchers have shown that
expression of 19-22nt shRNAs from U6 or Hl promoter is effective. It has been shown
that the size of the loop is not the main parameter for efficient gene silencing since some
several different sized loops have been efficient (31).
7

Brummolkamp et al., (32) designed a plasmid vector expressing shRNA against E
cadherin and p53 driven by the Hl promoter and coupled to a selective marker. Cell lines
transfected stably with the plasmid showed that specific silencing for more than 2 month.
Therefore, vectors expressing shRNA can be used for long-term gene silencing. In
addition, these vector systems can be used in cell lines having low transfection efficiency
because transfected cells can be selected by use of a reporter gene or selection marker.
Micro-RNA: The first micro-RNA was identified by Ambros and colleagues. They
isolated a lin4 mutant of C. elegans which was arrested at the first larval stage (33). Later
on, the let7 mutation was isolated in the same system, which was responsible for
development through the fourth larval stage (34). Both lin4 and let7 encode 22nt RNAs
and were called short temporal RNA because they control the development of C.elegans
temporally. The mature lin4 RNA inhibited the mRNA expression of lin14 and lin28
genes and controls the fate of cells during the first three larval stages. Recent studies have
revealed that the short temporal RNAs are members· of micro-RN A.
In D. melanogaster, C. elegans, plants and humans, more than 600 micro-RNAs have
been identified (25, 35, 36). An analysis of micro-RNA expression in cell lines and
tissues suggests cell or tissue specific expression. For example, micro-RNAl is
specifically expressed in human heart and stage specifically in mouse embryogenesis (36).
The regulated expression patterns of these micro-RNAs are suggestive of their functions
in developmental control.
Since micro-RNAs are derived from their precursor dsRNAs and are similar in size to
siRNAs, the generation of siRNA and micro-RNAs is similar. In fact, both siRNA and
micro-RNAs are processed by Dicer activities in animals as well as in plants (37- 39).
8

Human recombinant Dicer can process pre-let7 RNA to mature let7 efficiently in vitro
(40).

Delivery of siRNA
Transfection reagent: The most widely used method to deliver synthetic siRNA or
plasmid expressing shRNA into cells is transfection using a lipid-based transfection
reagent. This transfection reagent gives high transfection efficiency in some cell lines
including HeLa cell (41)
Electroporation: Some researchers have used electroporation to deliver synthetic
siRNA or plasmid producing shRNA to cells. However, many cells die after
electroporation (42)
Viral vector: Although plasmid vector mediated shRNAs mediate effective silencing,
it has the critical disadvantage of low transfection efficiency in many cells. Stable
transfection of the plasmid vector could be one solution. However, this process requires a
long time. To overcome this problem, several researchers developed new viral vector
systems (43-47).
1) Retrovirus vector
Retrovirus vectors integrate transgenes into host genome very efficiently, which
makes it possible for shRNAs to be constitutively expressed and silence the target mRNA
for long times. Because of this property, several retroviral vectors expressing shRNA
have been produced. For example, Paddison and Hannon (43) inserted U6 expression
cassette containing template for shRNA against p53 into a MMLV-based vector and
showed that infection of the vector silenced p53 stably.
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2) Lentivirus vector
Lentivirus vectors have two advantages over retrovirus vectors. First, lentivirus can
infect both dividing and non-dividing cells while retrovirus infect only dividing cells (44).
Second, retrovirus undergoes proviral silencing during development (45). However,
lentivirus vectors are resistant to this silencing. Several groups have used the lentivirus
vector to deliver shRNA to primary cells, which are not easily transfected. Stewart et al.
(31) transduced dendritic cells with a lentivirus vector to target endogenously expressed

GFP, and showed significant reduction of the target gene expression. Mouse and human
primary T cells also have been transduced with a lentivirus targeting CD25, or CCRS,
HIV-1 co-receptor expression. Mouse primary T cells transduced with a lentivirus

targeting CD25 showed significantly reduced proliferation in the presence of Il...-2 (46).
Targeting CCR5 in human peripheral T cells with lentivirus-derived shRNA showed a
10-fold reduced CCR5 expression and reduced infection when the cells were infected
with CCR5-tropic HIV-1 (47).
3) Adenovirus

Adenovirus has also been used to deliver shRNA in vivo (48). The advantages of
adenovirus vector are 1) high titers, 2) infection of dividing and non-dividing cells, and 3)
infection of various species and cell types. However, adenovirus vectors induce immune
responses and do not allow long-lasting expression of shRNA. Therefore, this delivery
system is not suitable for therapeutic purposes but can be used for short-term inhibition
for research purposes.
4) Adeno associated virus (AAV)
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Some researchers have used AAV vector to express shRNA in cells because it has
advantages (49) of infecting various cell types and both dividing and non-dividing cells.
In addition, it maintains long-term expression and has low immunogenicity. AAV
integrates at a preferred site, in human chromosome 19, but generally genomic insertion
is rare. Therefore, insertional mutation is not a big problem. However, the disadvantages
of AAV vector are that insert sizes are small and some patients may have pre-existing
antibodies against AAV.

Applications of RNAi
RNAi and functional genomics

RNAi has evolved into a powerful tool for identification of unknown gene function.
Specifically, the power of C.elegans and Drosophila genetics provides the opportunity to
use siRNA or shRNA libraries to identify genes rapidly which are responsible for the
specific phenotype. For example, Lee et al. (50) systemically inactivated 5690 genes in C.
elegans using siRNA to identify those involved in its life span. They found that mutation

of the leucyl-tRNA synthetase gene increased the life span. Recently several groups have
reported the method to construct siRNA or shRNA libraries (51, 52, 53, 54). Large-scale
screening using siRNA or shRNA libraries will make it easy to determine specific genes
which are responsible for distinct phenotypes.
Disease therapy

After the demonstration that siRNAs can silence genes in mammalian cells without an
interferon response, many studies have focused on disease treatment using RNAi
technology. The most widely studied disease models are viral diseases, cancers, and
11

genetic diseases. Because of the potency and specificity of siRNA, it is very attractive for
therapeutic purpose. However, there are important issues to be addressed before siRNA
becomes useful for therapy. First, there is no effective method for delivery of the siRNA
to the specific sites in vivo. Although some studies show efficient delivery in vivo (Table
2), delivering the RNAi to specific cells still limits its use in therapeutic applications in
humans. Second, potential toxicity of siRNA are uncertain in humans. Despite these
problems, many in vitro and some in vivo studies show potential for treatment of diseases

Targeting viral RNA with siRNA

siRNA has been shown to inhibit the production of a retrovirus, a negative-stranded
RNA virus, and a positive-stranded RNA virus. Cells transfected with siRNA
corresponding to the viral genome induced an obvious reduction in virus production,
indicating that viral RNA may be targeted by RNA silencing machinery.

HIV-1
Treating HIV-infected patients with combinations of antiviral drugs is reasonably
effective, but there are some problems concerning drug toxicity and the emergence of
drug-resistant HIV-1 strains. Since RNAi was demonstrated to be active in mammalian
cells and HIV-1 use RNA intermediates in their replication cycles, many researchers have
tried to use RNAi technology to inhibit HIV-1 replication as an alternative strategy (Fig.
3). Recently, several studies have shown that siRNAs can inhibit HIV-1 replication and
virus production in vitro (47, 55-63). These studies demonstrate that the targeting of early
or late viral transcripts, such as gag, pol, env, nef, rev, vif, or tat, may inhibit protein
12

expression and viral replication. Although HIV-1 production and replication may be
inhibited by RNAi, the question remains whether RNAi targets the incoming genomic
RNA, the newly synthesized transcripts, or both. If the incoming genomic viral RNA can
be targeted by RNAi, it will be helpful in preventing the cells from forming a provirus.
Evidence has suggested that RNAi does indeed target the incoming genomic RNA for
destruction (56, 58, 60). In these studies, the amount of the integrated provirus was found
to be reduced when cells were pre-treated with siRNAs. However, other studies showed
little or no reduction in integrated proviral DNA (55, 59, 62). It remains to be proved
whether incoming genomic DNA can be targeted effectively. However, it is clear that de
novo synthesized viral transcripts are degraded efficiently by siRNA. Tat is necessary for
efficient viral transcription after the establishment of a provirus. Therefore, targeting tat
mRNA reduces not only tat expression, but also the expression of other viral proteins.
Targeting the viral RNA directly presents a potential problem for clinical application
because of the high viral mutation rate. Mutational variants may escape being targeted.
Therefore, some researchers have used siRNA against cellular transcripts to inhibit the
infection of lflV-1. siRNA against CD4, which is the receptor for lilV-1, decreased HIV1 infection. The treatment of siRNA against CCR5 and CXCR4 also showed a 48% and
68% reduction in CCR5 and CXCR4 expression, and inhibited the CCR5 tropic and
CXCR4 tropic HIV-1 infections respectively (48,58, 64). Another host factor that is
important for lflV-1 replication is the transcription factor NF-KB. Binding NF-KB to
motifs in the LTR promoter of the integrated provirus is required for viral transcription.
A five-fold reduction in lilV-1 production was measured by silencing the p65 subunit of
NF-KB with siRNA (62). Although targeting the host co-factor has shown an effective
13

inhibition of HIV-1 production, the cellular co-factors have important roles in cellular
functions such as transcription (NF-KB) and immuno-regulation (CD4). Therefore,
targeting a co-factor with RNAi has negative effects. However, CCR5 is an exception.
Individuals who are defective for CCR5 show a resistance to infection from HIV-1 and
are healthy. Therefore, CCR5 siRNA may be a good candidate for the therapeutic
intervention of HIV-1 infections.

Other RNA Viruses
HCV is a major cause of chronic hepatitis and hepatocellular carcinoma. HCV
belongs to Flaviviridae with a positive single stranded RNA genome. Because there is no
cell culture system for HCV replication, RNAi studies have used replicon in Huh-7 cells
as a model for HCV replication. These replicons support HCV RNA transcription and
protein synthesis, but do not produce infectious viruses. Synthetic siRNAs against NS3
and NS5B, non-structural proteins, resulted in inhibition of HCV replication in vitro (6568). The internal ribosomal entry site (IRES) that is required for translation, has also been
targeted by synthetic siRNA or shRNA and shown strong inhibition of the replication.
(67-69).
The influenza A virus is a member of Orthomyxoviridae and a major cause of
infection of the human respiratory tract. The genome of influenza A virus is encoded by
eight segmented negative single stranded RNAs. It has been shown that siRNAs against
conserved regions of the influenza genome could inhibit virus production in cell culture
and embryonated chicken eggs (70). Among 20 siRNAs tested, those against
nucleocapsid (NP) and RNA polymerase (PA) reduced the accumulation of all eight viral
14

RNAs. The NP and PA proteins play an important role in viral transcription and
replication, so these siRNAs may be more effective than others.
For other RNA viruses, polio virus and respiratory syncytial virus (RSV), inhibition
of the viral replications ·and viral protein production was also demonstrated. The siRNA
against poliovirus capsid and RNA polymerase reduced viral titer in human cells (71),
and the P and F proteins of RSV were reduced by targeting their mRNA using siRNA
(72).

DNA Viruses
In contrast to RNA viruses, DNA viruses are less likely to escape from siRNA
because of their lower mutation frequency, but siRNAs against DNA viruses can only
target the viral mRNAs, and not the viral genomes. Nonetheless, efficient inhibition of
DNA viruses with siRNAs has been shown (73-76). For example, HBV is a member of
the Hepadnaviridae and its genome is a 3.2kb ds circular DNA. During infection, four
RNAs are transcribed that encode the coat protein (CP), polymerase (P), surface antigen
(S) and the transcription activator (X). HBV production in Huh-7 cells could be reduced
up to 20-fold by shRNA against the X mRNA (73). HBV is the first virus to be inhibited
by RNAi in vivo in mammals. When HBV and shRNA against HBV are co-delivered by
hydrodynamic injection, significant repression of HBV antigen expression in liver was
shown (74).
Recently, Bhuyan et al. have demonstrated that siRNA against Herpes Simplex Virus
-1 (HSV-1) can target viral mRNA (76). They target glycoprotein E, which mediates cell-
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to cell spread and immune evasion, and the transfection of the siRNA results in the
phenotype of a gE-deletion mutant virus in vitro.
Another DNA virus Human papillomavirus (HPV) is an important therapeutic target
because the constitutive expression of viral proteins E6 and E7 is required for
carcinogenic growth. Jiang and Milner have shown that targeting HPV E6 and E7 with
siRNA induces selective degradation of E6 and E7 mRNA in cells (77). Reduction of E6
with siRNA induces cell growth suppression and inhibition of E7 production causes
apoptosis (77).

RNAi as an Antiviral Therapy

These initial studies of the effect of RNAi on viral replication in mammalian cells
generated much hope for the use of RNAi as a novel antiviral therapy. However, there are
some obstacles to hurdle in order to use RNAi technology as a useful therapeutic strategy.
First, inhibition of viral replication using siRNA is largely based on transient transfection
of synthetic siRNAs. These synthetic siRNAs induce only temporal inhibition. An
approach for the long-term inhibition of viral replication has to be developed. shRNA
transcribed from plasmid or viral vector might be one solution, although shRNAs have
not yet been extensively employed.
A second problem is delivery of siRNA. So far no efficient delivery system has been
developed, although some in vivo experiments show positive signs. At this point the viral
vector seems to be the most reasonable approach. However, until an improved delivery
system is developed, RNAi technology might be used as a genetic tool for the viral study.
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Finally, as mentioned previously, viruses, especially, RNA viruses, are likely to evade
siRNA by mutations of the target sequences. Treatment of multiple siRNAs or targeting a
conserved sequence might be answers, but they have not yet been evaluated. An
alternative approach is targeting host mRNA instead of viral RNA. As mentioned, CCR5
is a good candidate for inhibition of HIV-1 infection. There is another example showing
prevention of virus-induced disease by silencing of host mRNA. HBV and HCV infection
trigger Fas -mediated apoptosis of hepatocytes. Song et al. showed that hydrodynamic
injection of siRNA against fas could block fulminant hepatitis induced by a fas-specific
antibody in mice (78). Hydrodynamically-injected siRNA against fas delivered to the
liver and showed that 82% of the treated mice survived for 10 days while control mice
died within 3 days (78). Hydrodynamic tail vein injection delivered siRNA or shRNA
mainly to the liver. Thus, this delivery method might be ideal to silence gene expression
in hepatocytes in mice. However, it has not been shown that this injection is effective in
humans.
Although many reports showing inhibition of viral replication with siRNA have been
published, therapeutical approach of siRNA is still limited by many problems concerning
the delivery, toxicity and viral escape. However, RNAi technology will elucidate the viral
gene function, and help to understand the interactions between viruses and their hosts.

Cancer

Tumor cells can result from uncontrolled cell growth mediated by oncogenic genes or
by resistance to cell death (apoptosis) by dysfunction of pro-apoptotic and/or anti
apoptotic molecules. Therefore, RNAi technology could be applied to inhibit oncogene or
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anti-apoptotic gene expression for cancer therapy. Cioca et al., (79) demonstrated
targeting oncogene c-raf and anti-apoptotic gene, bcl-2 in a myeloid leukemia cell line
decreased the protein expression level and induced apoptosis in the cell line. Other targets
for cancer therapy include pro angiogenic molecules because tumor cells require blood
supplies. Co-treatment of experimental tumors with chemotherapy and siRNA against
vascular endothelial growth factor (VEGF) showed promise for control of tumors (80).
Dominant genetic diseases

Another field in which siRNAs are being tested for therapeutic purposes is dominant
genetic diseases. Genetically dominant diseases result from mutation of one copy of the
gene even though the other copy of the gene is normal. Some in vitro studies have shown
that dominant genetic diseases might be treated by degradation of only the mutant
transcript targeted with siRNA (81, 82). For example, Only mutant transcripts of the sod
gene in amyotropic lateral sclerosis, tau gene in frontotemporal dementia, and app gene
in familial Alzheimer's disease were degraded in vitro (81-83). Therefore, dominant
genetic diseases caused by one or a few common mutations are good candidates for
clinical application of RNAi technology

WhysiRNA?
siRNA and antisense oligonucleotides share some features. They are nucleotides,
require delivery systems and induce post-transcriptional gene silencing. However, there
are also important differences between them. siRNAs are more potent and efficient for
the inhibition of target gene expression than antisense oligonucleotide (84,85). Although
there is a report claiming that siRNA and antisense oligonucletide have similar potency
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(86), many researchers believe siRNA is more potent and effective because siRNA is
naturally occurring as a form of microRNA and uses cellular machinery, while antisense
oligonucleotide does not exist naturally. Other advantage of siRNAs over antisense
oligonucleotide is that siRNA is highly effective without any chemical modifications,
while antisense oligonucleotide is not stable without chemical modification (87). This
lack of requirement of chemical modification of siRNA reduces toxicity of siRNA
compared to antisense oligonucleotides (88). In addition, the duration of gene silencing of
endogenous targets with siRNA is longer than that with chemically modified antisense
oligonucleotides (88). Therefore, longer inhibition, low toxicity and strong potency make
siRNAs better molecules to effect gene silencing. Another RNA molecule, ribozyme, has
been tried to inhibit gene expression, but its potency remains in question and there is no
sign of success as a potential therapeutics. Therefore, it appears that siRNA is a better
molecule to inhibit gene expression in vivo as well as in vitro.

RNAi in vivo
Although there are many articles claiming successful gene silencing with siRNA in
mammalian cell cultures, only limited reports in which siRNA is used in vivo have been
published because of lack of suitable delivery systems. The first paper where siRNA was
used in vivo was published in 2002. In the paper, Kay and colleagues co-injected NS5B
luciferase fusion gene with NS5B siRNA and then showed reduced luciferase expression
using bioluminescence imaging (89). Although they targeted exogenous gene by co
injection with corresponding siRNA, this was the first result demonstrating that siRNA
can induce RNAi in vivo. Several months later, Xia et al. demonstrated inhibition of
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endogenous gene expression with siRNA (90). They inhibited �-glucuronidase
production in the liver using adenovirus expressing shRNA. Many in vivo experiments
targeted liver cells because a delivery system is available. Tail vain injection with high
pressure, which is called hydrodynamic injection, delivers nucleic acid mainly to liver
cell. Fas, Caspase8, HCV, and HBV are targeted at the liver (Table 2). The brain is also
targeted by a few researchers. They delivered siRNA or shRNA into the brain by direct
local injection. AGRP, tyrosine hydrocyclase, and ataxin-1 are targeted in the brain (9193). Solid tumor cells are also easily accessible, so mutated p53, vascular endothelial
growth factor (VEGF), and endothelial growth factor receptor (EGFR) are targeted in
order to reduce tumor mass in vivo (80, 94, 95). Transforming Growth Factor-� (TGF-�),
CRX, and NRN, and VEGF are reduced in eyes by local injection (96-98). We
summarized in vivo experiments using siRNA or shRNA in Table 2. As shown in the
table, many in vivo experiments using systemic injection targeted the liver or other
particular tissues, such as the brain, eyes, and tumors are targeted because local injection
of siRNA or shRNA was possible. Because of the limited delivery system, application of
RNAi technology into mice has not reached its potential yet. However, RNAi does have

great potential if the development and improvement of delivery systems for RNAi
technology is achieved.

Specific Aims and Rationale
Pathogenesis of herpetic stromal keratitis (HSK) involves many molecules and a
complex mechanism (99). However, it has been shown that angiogenesis is a critical step
in the in development of HSK after herpes simplex virus-1 (HSV-1) infection (100).
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Treatment of neutralizing Ab against VEGF reduced angiogenesis and HSK severity
caused by HSV-1 infection (100). In addition, it has been demonstrated that inhibition of
IL-1 signaling, which is induced by HSV-1 infection, reduced VEGF production,
angiogenesis, and HSK severity (101). Therefore, it has been proposed that inhibition of
angiogenesis is a valuable approach to control HSK.
Recently, it has been shown that introduction of siRNA or shRNA into mammalian
cells inhibits target gene expression, which is called RNAi. Although the RNAi
technology has been successful in vitro, only limited in vivo experiments were published
because of delivery problems. Although most in vivo experiments target the liver, RNAi
technology was also successfully used in mouse eyes (96-98).
Therefore, in this study, we investigated the potential value of RNAi technology for
inhibition of angiogenesis-related gene expression in mouse eyes using intrastromal
injection. Treatment of plasmid expressing shRNA in vitro was performed to determine
whether shRNA can inhibit exogenous and endogenous target genes. More importantly, it
was also demonstrated that intrastromal injection of plasmid DNA expressing shRNA
against VEGF or IL-1 receptor type I can reduce angiogenesis induced by CpG motif and
IL-la treatment respectively. These studies demonstrating application of RNAi in mouse
eyes is a valuable approach in the study of corneal biology and in the treatment of corneal
diseases.
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Fig. 1 A model for the mechanism of RNAi.
Dicer enzyme processes the introduced long dsRNA into short interfering RNA
(siRNA). The siRNAs bind RISC and the complexes become activated by unwinding of
the siRNA. Such complexes degrade target mRNA.
This figure is adapted from Nature 418, 244-251(2002)
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Fig. 2 A role of the RNAi process in heterochromatinization in nuclear DNA.
dsRNA could inhibit gene expression by methylation of target DNA or histone protein.
This mechanism is studied mainly in plant and C.elegans.
This figure is adapted from Nature 430, 161-164 (2004)
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Fig. 3 RNA interference susceptible targets in the HIV-1 replication cycle.
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Tablel Inhibition of viral replication by RNAi.
Virus

Target gene

HIV

tat, rev

HIV

LTR, vif, nef

HIV

Cell type

Type of dsRNA

Ref

293/EcR

57

siRNA

Macrophage, PBLs

60

gag, CD4

siRNA

Macrophage, HeLa

58

HIV

gag, pol

siRNA

T cell line

59

HIV

gag, LTR

siRNA

U87

56

HIV

tat, rev

siRNA

Jurkat, HPBLs

55

HIV

env

siRNA

PBMC

61

plasmid based siRNA

HIV

CXCR4,CCR5

siRNA

U87

64

HIV

tat, RT, NF-KB

siRNA

Macrophage

62

HIV

nef

long dsRNA

U937, MT-4

63

HIV

CCR5

lentiviral shRNA

Macrophage

47

HCV

NS3, NS5B

siRNA

Huh-7

65

HCV

capsid, NS4B

siRNA

Huh-7.5

66

HCV

5'UTR

siRNA

Huh-7

67

HCV

5'UTR, NS3, NS5B

siRNA

Huh-7

68

siRNA
Plasmid based siRNA

Huh-7

69

SIKNA

tteLa �j,

fl

Plasmid based siRNA
HCV
1'0110 VITUS

5'UTR
caps1ct,po1ymerase

Mouse embryonic fibroblast
siRNA

70

Influenza

PBl, PB2, PA,

A virus

NP,M,NS

RSV

P and F proteins

siRNA

A549

72

HBV

X, core

retroviral shRNA

Huh-7

73

HBV

core, S, pol.,X

Plasmid based shRNA

Huh-7, mice

74

HBV

core

siRNA

Huh-7

75

HPV

E6,E7

siRNA

CASKi, siHa

77

HSV-1

gE

siRNA

keratinocytes

76

MOCK,
chicken empryos
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Table 2 Summary of in vivo RNAi experiments
Target gene

Target tissue

EGF P,Luciferase liver, spleen, kidney
Placental alkaline lung,pancreas
phosphatase

Type ofdsRNA
siRNA

Delivery
systemic injection.

Ref
106

AGRP

hypothalamus

plasmid based shRNA
siRNA

local injection

91

NS5B

mainly liver

plasmid base shRNA
siRNA

systemic injection.

89

(3-glucuronidase

liver

adenoviral shRNA

systemic injection

90

retroviral shRNA

in vitro transfection
and reconstitution

95

systemic injection

78

trp53

hematopoietic
stem cells

fas

liver

TNF-a

peritoneal cells

siRNA with DOTAP

ip injection

VEGF

retina

adenoviral shRNA

local injection

Caspase-8

liver

siRNA

systemic injection

102

VEGF

tumor

siRNA

local injection

80

S gene ofHBV

liver

siRNA

systemic injection
with pHBV

108

S gene ofHBV

liver

siRNA

107
98

plasmid based shRNA systemic injection

109

plasmid based shRNA systemic injection
with pegylated immunoliposome

110

Luciferase

implanted
brain tumor

P2X3

spinal cord

siRNA

local injection

103

Musk,rapsyn

muscle

siRNA

local injection

104

TGF-(3

subconjuntival

siRNA

local injection

96

EGFR

brain tumor

plasmid based shRNA systemic injection
with pegylated immunoliposome

Cxr,nrl

retina

plasmid based shRNA

NP,PAof
Influenza Avirus

lung

siRNA
with oligofectamine

ataxin-1
tyrosine
hydroxylase

brain midline
lobules IVN
midbrain neurons

in vivo electroporation
systemic inj. with
local injection (i.n.)

AAV mediated shRNA local injection
AAV mediated shRNA
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local injection

94

97
105
92
93

Part II

Reduction of murine VEGF gene expression and
angiogenesis caused by CpG motif in mouse eyes using
shRNA against VEGF
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Abstract
Neovascularization in the cornea can lead to impaired vision. Although many
molecules are involved in the neovascularization, vascular endothelial growth factor
(VEGF) is the one of the most strongly implicated factors in pathological
neovascularization of the eye. Therefore, VEGF is an attractive target for anti-angiogenic
therapy to treat neovascular eye disease. Recent developments in RNA interference
(RNAi) technology have made it possible to inhibit gene expression because the
technology allows for specific and potent gene silencing. In this study, we investigated
whether the plasmid DNA expressing shRNA against mVEGF (murine VEGF) can
reduce mVEGF expression and angiogenesis in a mouse corneal neovascularization
caused by CpG motif. Cells transfected with pshVEGF-EGFP, which expresses VEGF
shRNA and EGFP bicistronically, showed reduced mVEGF, mRNA, and protein levels.
In addition, the introduction of pshVEGF into the stromal cells of the mouse eyes by
intrastromal injection reduced the angiogenic area as well as mVEGF production caused
by CpG motif. Our results indicate that RNAi technology might be a useful approach to
studying corneal stromal cell biology and can be used to treat a variety of corneal
diseases induced by unwanted gene expression, such as neovascularization.
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Introduction
Neovascularization in the cornea is a critical step in herpetic stromal keratitis (HSK),
which is caused by ocular infection with the herpes simplex virus-l(HSV-1) (1, 2). The
mechanisms by which ocular infection of HSV-1 induces neovascularization are not clear.
However, it was demonstrated that bioactive CpG motif in HSV-1 DNA could contribute
to angiogenesis in the eyes, and the angiogenesis was mediated by mVEGF production
(3). In addition, the administration of the anti-mVEGF antibody prevents CpG-induced
angiogenesis in mouse eyes (3). These results imply that mVEGF is an important
molecule for neovascularization in mouse eyes and that inhibition of mVEGF production
can reduce angiogenesis in mouse eyes.
RNAi is a powerful technique used to induce gene silencing sequence specifically (4).

To investigate whether RNAi technology can inhibit mVEGF expression in vitro and in
vivo, we designed a plasmid DNA expressing mVEGF shRNA.

RNA interference (RNAi) is a phenomenon in which the introduction of double
stranded RNA (dsRNA) into certain organisms and cell types induces degradation of
homologous target mR.NA (4). RNAi was first discovered in C.elegans and it has
become clear that RNAi occurs in other organisms as well including fungi, Drosophila,
plants, and mammals (5, 6, 7, 8). There are a few different small RNA inducing RNAi,
including chemically synthesized siRNA and short hairpin RNA (shRNA) from the
plasmid or viral vector, and micro RNA (8, 9, 10, 11, 12). Among the small RNA,
synthetic siRNA is the most commonly used. However, synthetic siRNA requires cell
lines to have high transfection efficiency, but unfortunately, many cell lines and primary
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cells do not show high transfection efficiency. To overcome this limitation, we generated
plasmid DNA expressing mVEGF shRNA and EGFP bicistronically (pshVEGF- EGFP),
and sorted the EGFP positive cells after transfection to determine the inhibition of mRNA
of mVEGF. In the present study, we demonstrated that mVEGF mRNA is highly reduced
in pshVEGF-EGFP transfected cells, but not in pshGAPDH-EGFP (control plasmid)
transfected cells. This result indicates that shRNA expressing a plasmid containing
reporter gene is useful particularly when a cell line has a low transfection efficiency. We
also demonstrated that the intrastromal injection of pshVEGF into mouse stromal cells
reduced angiogenesis and m VEGF production induced by CpG motifs. These results
imply that the eye is a suitable organ for the application of RNAi technology and can help
to understand ocular biology and control ocular disease caused by unwanted gene
expression in corneal stromal cells.
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Materials and Methods
Mice

Five to six week old female BALB/c mice were used. All experiments were conducted in
compliance _with the guide for the care and use of Laboratory Animal Resource Council.
The animal facilities of the University of Tennessee (Knoxville, TN), used are accredited
by the American Association of Laboratory Animal Care. All ocular experimental
procedures were conducted according to the Association for Research in Vision and
Ophthalmology Resolution on the use and care of laboratory animals.

Plasmid construction

We designed shRNA to interfere with mVEGF expression, referring to technical
information (Ambion, Austin, TX). The target sequence was confirmed to determine
there is no homology to any other mouse genes by using a BLAST search. The 19-mer
sense shRNA sequence and antisense shRNA sequence were linked with a nine
nucleotide spacer (TICAAGAGA) as a loop. Six Ts and 6As were added as a
termination signal to the 3' end of the forward oligomer and 5'end of the reverse
oligomers, respectively. Then 4 nucleoti�es corresponding to the EcoRI (AATI) and
Apal (GGCC) sites were added to the 5' and 3' end of the reverse oligomer, respectively.
The oligomer sequences for pshVEGF are (forward) 5'-OCTACTGCCGTCCAATIO
ATTCAAGAGATCAATIGGACGGCAGTAGCTTmT-3' (reverse) 5'-AATIAAAA
AAGCTACTGCCGTCCAATTGATCTCTIGAATCAATIGGACGGCAGTAGCGGC
C-3'.
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The forward and reverse oligomers were incubated in annealing buffer (100mM K
acetate, 30mM HEPES-KOH (pH7.4) and 2mM Mg-acetate) for3 min at 90oC, followed
by incubation for 1hr at 37oC. The annealed oligomer was legated with linearized
pSilencerl.0-U6 vector (Ambion) at Apal and EcoRI sites. After transformation, the
sequence was confirmed by DNA sequencing. pshGAPDH was purchased from ambion
(Austin, TX). For pshVEGF-EGFP and pshGAPDH-EGFP, DNA fragment containing
CMV promoter, EGFP gene, and polyA sequence was inserted at Sacl site using blunt
end ligation.

Cell culture and transfection

Cos-7 and MBE cells were cultured in DMEM (Mediatech, VA) supplemented with 10%
heat-inactivated FBS and penicillin/streptomycin in 5% CO2. Cells were reseeded at a
confluency of 70-80% in the absence of antibiotics 1 day before transfection.
Transfection with plasmids was carried out with Lipofectamine 2000 (lnvitrogen)
according to the manufacturer's specifications.

Reagents

Phosphorothioate ODNs were kindly provided by Dennis M. Klinman (Biologics
Evaluation and Research, Food and Drug Administration, Washington, DC). The
sequences of stimulatory ODNs used in this study were: 1466, TCAACGTIGA, and
1555, GCTAGACGTIAGCGT. Subsequent studies were performed using an equimolar
mixture of ODNs 1466 and 1555. The control ODN 1471 has sequence TCAAGCTIGA.
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Total RNA isolation and RT-PCR

Total RNA from cells was extracted by using RNeasy RNA extraction kit (Qiagen,
Valencia, CA). Briefly, cells were lysed in lysis buffer, and RNA was purified following
manufacturer's protocol. DNase treatment (Qiagen) was done to remove genomic DNA.
For the RT-PCR, one-step RT-PCR was performed according to the manufacturer's
protocol (Qiagen) with 80ng of total RNA. The following RT-PCR conditions were used:
1 cycle of 50°C for 30 min followed by lcycle of 94°C for 2 min: 30 cycles of 94°C for 1
min, 56°C for 1 min and 72°C for 1 min and a final cycle of 72°C for 5 min. The primer
sequences for VEGF were 5'-GCGGGCTGCCTCGCAGTC-3' (forward) and 5'TCACCGCCTIGGCTIGTCAC-3' (reverse). The primer sequences for GAPDH were
5'-CA TCCTGCACCACCAACTGCTIAG (forward) and 5'GCCTGCTICACCACCTICTIGATG-3' (reverse).

Quantitative Real-Time PCR

Total RNA was isolated from GFP positive cells after transfection using RNeasy RNA
extraction kit (Qiagen) according to manufacturer's protocol. DNase(Qiagen) was treated
to remove genomic DNA. To generate cDNA lug of total RNA was reverse
transcriptased using reverse transcriptase ( Invitrogen). All cDNA samples were
aliquoted and stored at -20oC until use. Real time PCR was performed using a smart
cycler system (Chepheid). PCR was performed using SYBR Green I reagent (Qiagen),
according to the manufacturer's protocol. The semi-quantitative comparison between
samples was calculated as follows: the data were normalized by subtracting the difference
of the threshold cycles (Ct) between the gene of interest's Ct and the GAPDH's Ct (gene
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of interest Ct - GAPDH Ct = ACt) for each sample. Then, MCt was calculated by
subtraction (AACt = ACt, pshVEGF- ACt, pshGAPDH). To determine relative expression
of VEGF mRNA following formula was used 2-Mct_
The primers used were GAPDH 5'-CATCCTGCACCACCAACTGCTIAG-3' (forward),
5'-GCCTGCTICACCACCTTCTIGATG-3' (reverse), VEGF 5'-GGAGATCCTI
CGAGGAGCACTT-3' (forward), 5'-GGCGATTTAGCAGCAGATATAAGAA-3'
(reverse).

Flow cytometry

Trypsinized cells were fixed and permeabilized using cytofix/cytoperm buffer (BD
Biosciences, Mountain View, CA) for 30 minutes on ice. Labeling of intracellular VEGF
was carried out with biotinylated VEGF antibody (R&D systems, Inc., Minneapolis, MN)
followed by staining with streptavidin-PE. Finally, the cells were washed three times and
samples were acquired on a FACScan (BD Bioscience). The data were analyzed using the
CellQuest 3.1 software (BD Biosciences).

Corneal lysate VEGF Enzyme-Linked Immunosorbent Assay (ELISA)

Corneas were isolated and put into DMEM without serum and stored at -80°C. The
corneas were homogenized using ultra sonicater (Heat systems-Ultrasonics, NY). The
lysate was then clarified by centrifugation at 12000rpm for 5 minutes at 4°C. The
supernatant was collected and stored at -80°C until further use. Lysate was assayed using
a standard sandwich ELISA protocol. Anti-mouse VEGF capture and biotinylated
detection antibody (R&D systems, Inc., Minneapolis, MN) was used. mVEGF164 protein
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was used as a standard (R&D systems, Inc.). The color reaction was developed using
ABTS (Sigma-Aldrich, St. Louis, MO) and measured with an ELISA reader (Spectramax
340; Molecular Devices, Sunnyvale, CA) at 405nm. Quantification was petformed with
Spectramax ELISA reader software version 1.2.

lntrastromal injection

Corneal intrastromal injection was petformed as described before (13). Under
stereomicroscopic observation, a small tunnel from the corneal epithelium to the anterior
stroma was made with a one-half-inch 30-gauge needle. Another needle was passed
through the tunnel into the corneal stroma. Two microliters of solution containing the 1ug
plasmid was forcibly injected into the stroma.

Corneal Micropocket Assay

The corneal micropocket assay used in this study observed the general protocol of
Kenyon and colleagues (14)
Pellets 0.4x 0.4x 0.2mm3 composed of sucralfate and hydron polymer were prepared.
Known amount of bioactive CpG or non-bioactive control CpG were added to these
pellets. Each pellet contains lug of CpG ODNs. The micropockets were placed -1 mm
from the limbus under stereomicroscope (Leica Micro Systems, Wetzlar, Germany) and
the pellet was inserted into the micropocket.

Measurement of angiogenic area

Angiogenesis area was measured at day4 after pellet implantation by using caliper
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(Biomedical Research instrument, Rockville, MD) with a streomicroscope.
The length of the neovessels generated from the limbal vessel ring toward the center of
the cornea and the width of the neovessels presented in clock hours ( each clock hour is
equal to 30° at the circumference) was measured (15). The angiogenic area was
calculated according to he formula for an ellipse. A= [(clock hours) x 0.4 x (vessel length
in mm) x 1t]/2.

Statistical analysis

Significant differences between groups were evaluated using student's t-test. A p value of
g).05 was regarded as indicating a significant difference between two groups.
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Results
Selection of candidate sequences and construction plasmid
To select candidate target sequences, we used siRNA target finder on the website of
ambion. The program scans the mVEGF sequence for the 21 nucleotide sequence starting
AA. From among them, we chose three sequences having less than 50% G/C content
because siRNAs with low G/C content are more active than those with higher G/C
contents, according to the technical information from ambion. After the selection
candidate sequence, we inserted an oligonucleotide having sense, loop, and anti-sense
sequence into a shRNA expressing vector (pshVEGF) (Fig. lA). To make plasmid
expressing shRNA and EGFP bicistronically, we inserted an EGFP gene containing CMV
promoter and a poly A sequence (pshVEGF-EGFP) (Fig. lB). With this pshVEGF-EGFP,
we validated effective sequence.

Co-transfection of pshVEGF and pEGFP-VEGF reduced EGFP signal.
Validation of an effective shRNA requires determination of the mRNA and protein
levels using RT-PCR, a northern blot, a western blot, or flow cytometry. To make this
validation step simple, we designed pEGFP-VEGF (Fig. lC) and co-transfected it with
pshVEGF into Cos-7 cells. If mVEGF shRNA degrades its target mRNA, EGFP mRNA
can not be translated either. Co-transfection of pshVEGF and pEGFP-VEGF showed a
reduced EGFP signal in compared to the co-transfection of pshGAPDH, expressing
GAPDH shRNA and pEGFP-VEGF (Fig. 2). From this experiment, we chose the most
effective shRNA for the rest of the experiment.
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To determine the Mean Fluorescence Intensity (MFI) after co-transfection of pEGFP
VEGF with psh VEGF or pshGAPDH, flow cytometcy was performed. The MFI of the
cells which were co-transfected with pEGFP-VEGF and pshGAPDH was 330.29 ± 29.69,
while the MFI of the cells which were co-transfected with pEGFP-VEGF and pshVEGF
was 110.56 ± 16.39 (Fig. 3). These results indicate that pshVEGF targets VEGF mRNA
effectively. In addition, it was shown that the co-transfection of shRNA with the plasmid
expressing reporter gene-target gene mRNA is a useful tool to validate a shRNA
candidate. This strategy might be useful, especially in case when antibodies against target
proteins are not available.

pshVEGF-EGFP reduced endogenous VEGF gene expression in transfected cells.

The MBE cell line revealed a very low transfection efficiency (5-10%). Therefore, we
could not detect a significant reduction of gene expression after the transfection. To solve
this problem, we designed pshVEGF-EGFP and pshGAPDH-EGFP expressing shRNA
and EGFP bicistronically (Fig. lB). After the transfection of the plasmid, we sorted the
EGFP positive cells prior to performing RT-PCR and real time PCR. The pshVEGF
EGFP positive cells suppressed 70% of mVEGF mRNA compared to the control cells,
which were pshGAPDH-EGFP positive cells (Fig.4, 5). We also determined whether
pshVEGF reduces the VEGF protein in MBE cells. In cells transfected with pshVEGF
EGFP, the EGFP positive cells showed a reduced mVEGF protein level. The MFI of
mVEGF from the pshVEGF-EGFP transfected cells.(EGFP positive cells) was 42.6 ±
15.6, while the MFI of mVEGF from the pshGAPDH-EGFP transfected cells was 104.1±
16.6. The MFI of mVEGF from the untrasfected cells was similar to that of the
58

pshGAPDH-EGFP transfected cells (98.6± 15.7 and 99.6± 10.2 respectively) (Fig.6).
Intrastromal co-injection of pshVEGF and pEGFP-VEGF reduced EGFP signal in
cornea
To determine that how much plasmid DNA is required to obtain optimal transfection,
we injected 0.5, 1.0, 2.0, 4.0 or 8.0ug/2ul per eye with pEGFP. Intrastromal injection
with 1.0 -4.0ug/2ul showed similar highest GFP signal. Therefore, we used 2ug/2ul dose
for our experiments. In addition, we also investigated how long plasmid is expressed into
stromal cells. We observed GFP signal from day 1 to day 10 after intrastromal injection.
GFP signal was strong until day3. At day 4 the signal started decreasing. However, the
signal was detected until day 8 or 9. Therefore, it seems that plasmid based shRNA is
expressed long enough to see the effect in vivo.
To determine whether the shRNA against mVEGF degrades its target molecule in the
cornea, we co-transfected pshVEGF and pEGFP-VEGF intrastromally. A's a control,
pshGAPDH and pEGFP-VEGF were co-injected. The co-injection of pshVEGF and
pEGFP-VEGF showed a reduced EGFP signal compared to the co-injection of
pshGAPDH and pEGFP-VEGF (Fig. 7). This result indicates that psh VEGF degrades its
target mRNA in the stromal cells of the mouse cornea.

Intrastromal injection of pshVEGF reduced angiogenesis caused by CpG motif
To investigate whether pshVEGF can reduce angiogenesis in mouse eyes, pshVEGF
or pshGFP was injected intrastromally. One day after injection, a pellet containing
bioactive CpG or bioinactive CpG oligonucleotide was implanted to cause angiogenesis.
Four days after implantation, an angiogenic area was measured. The pshVEGF-injected
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eyes showed reduced angiogenesis compared to pshGFP-injected eyes (Fig. 8). The
angiogenic area from the psh VEGF-injected eyes was 0.34 ± 0.11, while the area from
the pshGFP-injected eyes was 0.49 ± 0.14 mm2• The angiogenic area from co�trol CpG
implanted eyes was 0.15 ± 0.11 mm2 (Fig. 9).
The level of the mVEGFl 64 protein was measured by ELISA. An intrastromal
injection of pshVEGF reduced the mVEGF164 protein level (126.67 ± 16.07pg / eye) in
bioactive CpG-treated cornea in compared to the injection of pshGFP (183.33 ± 48.05pg /
eye) (Table 1). Therefore, it is assumed that the reduction of the mVEGF protein results
in the inhibition of angiogenesis in the mouse cornea.
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Discussion
RNAi phenomenon was discovered very recently, but the RNAi technology has been
used in many research areas because it is very powerful to reduce endogenous gene
expression with specificity. The most popular purpose of the experiment using RNAi
technology is to identify unknown biological gene function. The conventional way to
identify the function of particular genes is the examination of mutant or knockout
phenotype. However, all mutant and knockout animals are not available and making them
is a time consuming process. On the �ther hand, it is relatively easy and quick to reduce
particular gene expression using RNAi technology to determine function of the interested
genes. Additionally, in C.elegans, high throughput screening format, in which many
genes can be screened at a time to find genes having particular function, using siRNA has
been developed and identified the genes involved in cell division and embryonic
development (16, 17). This RNAi pathway is conserved from plants to mammals, so this
technology can be used in many organisms.
To determine reduced protein level after transfection of siRNA or shRNA, antibodies
against target proteins are required. However, some antibodies are not available. To
overcome this problem, we designed co-transfection strategy in which plasmid
expressing fusion protein (reporter protein-target protein) and shRNA are co-transfected.
The result showed that co-transfection of pEGFP-VEGF and pshVEGF reduced EGFP
signal (Fig.2). Therefore, this strategy might be useful to detect suppression of protein
production indirectly when a antibody against target protein is not available.
Although the RNAi technology is very useful, it depends on high transfection
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efficiency. Therefore, most experiments have been done with only cell lines having high
transfection efficiency such as HeLa and HEK 293 cells. To overcome this limitation, we
have designed plasmid expressing a shRNA and a reporter gene, EGFP, bicistronically
(pshVEGF-EGFP) to identify which cells are transfected. After transfection of the
plasmid into MBE cell line having low transfection efficiency, we sorted EGFP positive
cells (pshVEGF-EGFP transfected cells) and showed down regulation of mVEGF mRNA
in the sorted cell in comparison with the pshGAPDH-EGFP transfected cells (Fig.4, Fig.
5). In addition, flow cytometry experiment showed that pshVEGF-EGFP positive cells
produced less mVEGF in comparison with pshVEGF-EGFP negative cells or
pshGAPDH-EGFP positive cells. Therefore, these results imply that the plasmid
expressing shRNA and EGFP is useful in cell lines having low transfection efficiency.
SiRNA degrades mRNA sequence specifically so, RNAi technology can be used for
therapeutic purposes. Although down regulation of unwanted gene or mutated gene
expression is an attractive method to treat disease and siRNA has the potential, the
delivery of siRNA to proper cells or tissues is a problem for the therapeutic application of
siRNA. Recently, the therapeutic potential of the siRNA was demonstrated in the mouse.
Song et. al. (18) demonstrated that targeting of fas mRNA by fas siRNA decrease
hepatocyte necrosis and protected mice from liver fibrosis and fulminant hepatitis. One of
the critical reasons their in vivo experiment was successful is that the hydrodynamic
injection delivers most siRNAs to the liver cells. However, this technique may not be
used for large animals because the pressure may not reach to the liver in such animals.
Direct injection into tissues is also used to deliver siRNA or viral vector mediated shRNA
(19, 20). This method could achieve tissue or organ specific delivery of siRNA or shRNA.
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However, it is used only in limited tissues or organs because direct injection is not
available in many tissues. Viral vectors are being used by many researchers (21-25).
Some viral vectors give good transduction efficiency but lack of tissue specific
transduction could be a problem. Development of tissue specific promoter-derived
shRNA might be the answer of the problem.
In this study, we showed that intrastromal co-injection of pshVEGF and pEGFP
VEGF reduced EGFP signal in comparison with co-injection of pshGAPDH and pEGFP
VEGF (Fig. 7). In addition, intrastromal injection of pshVEGF reduced angiogenesis and
mVEGF protein production caused by CpG motif in eyes (Fig. 8, Fig.9, and Table 1). At
this time, we do not know how many cells are transfected by pshIL-lRI. However we
assumed that intrastromal injection transfected enough cells to reduce angiogenesis
caused by the IL-la. treatment. Otherwise, shRNA might be spread to neighbor cells after
expressed in transfected cells and inhibit target protein expression in untransfected cells
as well as transfected cells. Although improvement of delivery system is necessary for
more successful gene silencing, it seems that the eye might be a good target organ to use
RNAi technology for such research and therapeutic purposes. Our results imply that
RNAi technology may be helpful to understand corneal biology and hold promise for the

development of gene specific therapeutics in eyes.
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Fig. 1 plasmid constructs 1.
A. pshVEGF expresses shRNA against mVEGF
B. pshVEGF-EGFP expresses shRNA against mVEGF and EGFP bicistronically
C. pEGFP-VEGF expresses EGFP-VEGF fusion protein
Sense: sense sequence, Antisense: antisense sequence,
Term: RNA polymerase III transcription termination sequence
CMV: CMV promoter, Poly A: Poly A sequence
Arrows represent transcription start site and direction
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poly A

Fig. 2 Fluorescence microscopy after co-transfection of pVEGF-EGFP with pshVEGF or
pshGAPDH.
0.5ug of pEGFP-VEGF with 2ug of pshGAPDH (A) or 2ug of pshVEGF (B) are co
transfected. 24hrs after transfection fluorescence microscopy was performed.
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A. pEGFP-VEGP + pshGAPDH

B. pEGFP-VEGF + pshVEGF

Fig.2
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Fig.3 Inhibition of exogenous mVEGF protein.
24-36 hrs after co-transfection of pEGFP-VEGF with pshGAPDH (A) or pshVEGF
(B) into cos-7 cells, flow cytometry was performed.
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10"

Fig. 4 Inhibition of endogenous mRNA of mVEGF.
pshGAPDH-EGFP positive and pshVEGF-EGFP positive cells were sorted .
Total RNA from the sorted cells was isolated and RT-PCR was performed.
Beta actin primers were used as a control.
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Fig. 5 Relative quantitation of reduced mRNA of mVEGF.
After EGFP positive cell sorting, total RNA was isolated, and then cDNAs were
made from the total RNA. MCt method was used to compare the relative
expression of mRNA between the cells
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Fig. 6 Inhibition of endogenous mVEGP protein.
24hr after transfection of pshGAPDH-EGFP (B) or pshVEGF-EGFP (C), cells
were harvested for intracellular staining to detect mVEGF protein. (A): isotype
control antibody was treated.
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42.6± 15.6

Fig. 7 Reduction of VEGF-EGFP signal by intrastromal injection of pshVEGF in
mouse cornea.
Co-injection of pEGFP-VEGF with pshGAPDH (A) or pshVEGF (B) was
performed.
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Fig. 8 Reduction of angiogenesis caused by CpG motifs by pshVEGF in cornea.
Intrastromal injection of pshVEGF (B) reduced angiogenesis induced by CpG
motifs. pshGFP (A) was used as a control plasmid. Bioinactive CpG was
used as a control pellet (C)
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A. pshGFP + CpG

B. pshVEGF + CpG

Fig.8
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C. pshGFP + control CpG

Fig. 9 Angiogenesis area at day 4 after CpG treatment following pshGFP or pshVEGF
Injection.
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pshVEGF
bioinactive CpG * p< 0.007

Table 1. Measurement of the amount of mVEGF in corneas using ELISA

Plasmid

pshGFP

pshVEGF

CpG

bioactive

bioactive

VEGF

183.33± 48.05

pshGFP
bioinacti ve (control)

*126.67± 16.07 * 101.67 ± 23.09

pg/ eye
* p< 0.05
Four days after CpG treatment following pshGFP or psh VEGF
injection ELISA was performed.
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PART III

Inhibition of angiogenesis caused by IL-la in mouse
cornea using shRNA against IL-1 receptor type I
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Abstract
Ocular infection with herpes simplex virus-1 (HSV-1) induces IL-1, which is a pro
inflammatory cytokine. Subsequently, the IL-1 protein induces the production of many
other molecules, such as IL-6 and vascular endothelial growth factor (VEGF), a potent
angiogenic factor, which results in neovascularization in the cornea. Therefore, the
inhibition of IL-1 signaling is a useful strategy to reduce angiogenesis caused by IL-1 in
the cornea.
In this study, we demonstrated that the intrastromal injection of plasmid-based
shRNA against IL-1 receptor type I (IL-lRI) reduced angiogenesis caused by IL-la in
the cornea when it was compared to control shRNA-treated cornea. We also showed that
the intrastromal injection of IL-lRI shRNA reduced.VEGF production which is induced
by IL-la. This result implies that reduced angiogenesis by IL-lRI shRNA might be
mediated by reduced VEGF expression. Although the IL-1 receptor antagonist (IL-lRa)
is widely used to interrupt IL-1 and IL-lRI interaction, our results indicated that the
inhibition of IL-lRI expression using IL-lRI shRNA might be another valuable approach
to treat the diseases caused by IL-1.
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Introduction
Herpes simplex virus-I (HSV-1) infection of the mouse eyes causes herpetic stromal
keratitis (HSK), which results in blindness. After an HSV-1 infection, many cellular
events are involved in the pathogenesis of HSK (1). Among them, neovascularization is a
critical step in HSK pathogenesis, and the VEGF protein is a major angiogenic factor. It
was shown that the inhibition of VEGF using a neutralizing antibody reduced HSK
severity as well as angiogenesis caused by the HSV-1 infection (2, 3). In other
experiments, it was shown that the HSV-1 infection induced IL-1 and IL-6, and the
increased expression of the cytokines stimulated angiogenesis through up-regulation of
VEGF (4). In addition, the transgenic mouse that over-expresses the IL-1 receptor
antagonist (IL-lRa) showed reduced HSK severity and angiogenesis in comparison to the
wild type mice (4). IL-lRa binds to the IL-1 receptor type I without transmitting an
activation signal (5). Thus it represents a physiological inhibitor of IL-1 activity. These
results imply that IL-1 production is a critical event in the development of HSK and
inhibition of the IL-1 and IL-1 receptor interaction can be a useful approach to control
angiogenesis and HSK.
There are two forms of IL-1 proteins, IL-1a. and IL-1 �' which are the products of
distinct genes (6, 7). In most studies, their biological activities are indistinguishable, and
they bind to the same receptors: IL-1 receptor type I (IL-lRI) and IL-1 receptor type Il.
(IL-IR Il) (5). Type I receptor is an 80kDa transmembrane protein with an IL-1 signaling
function. On the other hand, IL-IR type II is a 68kDa membrane protein with a short
cytoplasmic tail and has no signaling function (5).
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In this study, we demonstrated that the inhibition of IL-lR type 1 (IL-lRI) expression
. using RNAi (RNA interference) technology can reduce angiogenesis caused by the IL-la
protein in mouse eyes.
RNAi is a sequence-specific gene silencing mechanism initiated by the introduction
of double-stranded RNA (dsRNA) into target cells (8). RNAi is mediated by small
interfering RNAs (siRNAs) produced from long dsRNAs of exogenous or endogenous
origin by an endonuclease called Dicer. The resulting siRNAs are about 21 to 23
nucleotides long and are incorporated into a RNA-induced silencing complex, which then
targets and cleaves the mRNAs that are complementary to the siRNAs (9,10). In
mammalian cells, the introduction of 19-21 nucleotide siRNA duplex is required to
initiate RNAi without non-specific gene silencing (11). DNA plasmids expressing
shRNAs have been shown to induce RNAi successfully (12-14).
We demonstrated that transfected cells with the plasmid expressing shRNA against
IL-lRI reduced IL-lRI expression in vitro. In addition, intrastromal injection of the
pshIL-lRI into mouse eyes showed red�ced angiogenesis and VEGF production in
comparison to control plasmid-injected eyes. Our results imply that targeting IL-lRI
using shRNA can be a valuable approach to treat the disease caused by unwanted IL-1
production, such as HSK.
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Materials and Methods
Mice

Five to six week old female BALB/c mice were used. All experiments were
conducted in compliance with the guide for the care and use of Laboratory Animal
Resource Council. The animal facilities of the University of Tennessee (Knoxville, TN),
used are accredited by the American Association of Laboratory Animal Care. All ocular
experimental procedures were conducted according to the Association for Research in
Vision and Ophthalmology Resolution on the use and care of laboratory animals

Plasmid construction

We designed shRNA to interfere with IL-lRI expression, referring to technical
information (Ambion, Austin, TX). The target sequence was confirmed to determine
there is no homology to any other mouse genes by using a BLAST search. The 19-mer
sense shRNA sequence and antisense shRNA sequence were linked with a nine
nucleotide spacer (TICAAGAGA) as a loop. Six Ts and six As were added as a
termination signal to the 3' end of the forward oligomer and 5'end of the reverse
oligomers, respectively. Then 4 nucleotides corresponding to the EcoRI (AATI) and
Apal (GGCC) sites were added to the 5' and 3' end of the reverse oligomer, respectively.
The oligomer sequences for pshIL-lRI are (forward) 5'-GAAAGACCACAGTCTGC
AATI CAAGAGATIGCAGACTGTGGTCTITCI 1111 l'-3', (reverse)5'-AATIAAA
AAAG AAGACCACAGTCTGCAATCTCTIGAATIGCAGACTGTGGTCTITCGGC
C-3'.
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The forward and reverse oligomers were incubated in annealing buffer (l00mM K
acetate, 30mM HEPES-KOH (pH7.4) and 2mM Mg-acetate) for3 min at 90oC, followed
by incubation for 1hr at 37oC. The annealed oligomer was legated with linearized
pSilencerl.0-U6 vector (Ambion) at Apal and EcoRI sites. After transformation, the
sequence was confirmed by DNA sequencing. pshGAPDH was purchased from ambion
(Austin, TX). For pshVEGF-EGFP and pshGAPDH-EGFP, DNA fragment containing
CMV promoter, EGFP gene, and polyA sequence was inserted at Sacl site using blunt
end ligation.

Cell culture and transfection

Cos-7 and LEU cells were cultured in DMEM (Mediatech, VA), supplemented with
10% heat-inactivated FBS and penicillin/streptomycin in 5% CO2. Cells were reseeded at
a confluency of 70-80% in the absence of antibiotics lday before transfection.
Transfection with plasmids was carried out with Lipofectamine 2000 (Invitrogen)
according to the manufacturer's specifications.

Total RNA isolation and RT-PCR

Total RNA from the cells was extracted by using an RNeasy RNA extraction kit
(Qiagen, Valencia, CA). Briefly, cells were lysed in a lysis buffer, and the RNA was
purified following the manufacturer's protocol. DNase treatment (Qiagen) was performed
to remove genomic DNA.
For the RT-PCR, one-step RT-PCR was performed according to the manufacturer's
protocol (Qiagen) with 80ng of total RNA. The following RT-PCR conditions were used:

94

1 cycle of 50°C for 30 min followed by lcycle of 94°C for 2 min: 30 cycles of 94°C for 1
min, 56°C for 1min and 72°C for 1 min and a final cycle of 72°C for 5 min. The primer
sequences for IL-lRI were 5'-ACCCCCATATCAGCGGACCG-3' (forward) and 5'
TTGCTTCCCCCGGAACGTAT-3' (reverse). The primer sequences for GAPDH were
5'-CATCCTGCACCACCAACTGCTTAG (forward) and 5'
GCCTGCTTCACCACCTTCTTGATG-3' (reverse).

Flow cytometry
Trypsinized cells were fixed and permeabilized using cytofix/cytoperm buffer (BD
Biosciences, Mountain View, CA) for 30 minutes on ice. Labeling intracellular mVEGF
was carried out with the biotinylated mVEGF antibody (R&D systems, Inc., Minneapolis,
MN)and followed by staining with streptavidin-PE. Finally, the cells were washed three
times and samples were acquired on a FACScan (BD Bioscience). The data were
analyzed using CellQuest 3.1 software (BD Biosciences).

Corneal lysate VEGF Enzyme-Linked Immunosorbent Assay (ELISA)
Corneas were isolated and put into DMEM without serum and stored at -80°C. The
corneas were homogenized using an ultra sonicater (Heat systems-Ultrasonics, NY). The
lysate was then clarified by centrifugation at 12000rpm for 5 minutes at 4°C. The
supernatant was collected and stored at -80°C until further use. Lysate was assayed using
a standard sandwich ELISA protocol. Anti-mouse VEGF capture and biotinylated
detection antibody (R&D systems, Inc., Minneapolis, MN) were used. The mVEGF164
protein was used as a standard (R&D systems, Inc.). The color reaction was developed
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using ABTS (Sigma-Aldrich, St. Louis, MO) and measured with an ELISA reader
(Spectramax 340; Molecular Devices, Sunnyvale, CA) at 405nm. Quantification was
performed with Spectramax ELISA reader software version 1.2.

Intrastromal injection

Corneal intrastromal injection was performed as described before (15). Under
stereomicroscopic observation, a small tunnel from the corneal epithelium to the anterior
stroma was made with a one-half-inch 30-gauge needle. Another needle was passed
through the tunnel into the corneal stroma. Two microliters of solution containing 1 ug
plasmid was forcibly injected into the stroma.

Corneal Micropocket Assay

The corneal micropocket assay used in this study observed the general protocol of
Kenyon and colleagues (16).
Pellets 0.4x 0.4x 0.2mm3 composed of sucralfate and hydron polymer were prepared. A
known amount of bioactive CpG or non-bioactive control CpG was added to the pellets.
Each pellet contained lug of CpG ODNs. The micropockets were placed -1 mm from the
limbus under a stereomicroscope (Leica Micro Systems, Wetzlar, Germany) and the
pellet was inserted into the micropocket.

Measurement of the angiogenic area

The angiogenesis area was measured at day4 after pellet implantation by using caliper
(Biomedical Research instrument, Rockville, MD) under a streomicroscope.
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The length of the neovessels generated from the limbal vessel ring toward the center of
the cornea, and the width of the neovessels presented in clock hours ( each clock hour is
equal to 30° at the circumference) was measured (17). The angiogenic area was
calculated according to the formula for an ellipse. A= [(clock hours) x 0.4 x (vessel
length in mm) x 1t]/2.

Statistical analysis

Significant differences between groups were evaluated using student's t-test. A p
value of �.05 was regarded as indicating a significant difference between two groups.
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Results
Selection of candidate sequences and construction plasmid
To select candidate target sequences, we used siRNA target finder on the website of
ambion. The program scans the IL-lRI sequences for the 21 nucleotide sequences
starting AA. From among them, we chose three sequences having less than 50% G/C
content because siRNAs with low G/C content are more active than those with higher
G/C contents, according to the technical information from ambion. After the selection
candidate sequence, we inserted an oligonucleotide having sense, loop, and anti-sense
sequence into a shRNA expressing vector (pshVEGF) (Fig. lA). To make plasmid
expressing shRNA and EGFP bicistronically, we inserted an EGFP gene containing CMV
promoter and a poly A sequence (pshVEGF-EGFP) (Fig. lB). With this pshIL-lRI-EGFP,
we validated effective sequence.

Reduction of the IL-lRI protein in transfected cells with pshIL-lRI-EGFP
pshIL-lRI-EGFP or pshGAPDH-EGFP was transfected into °LEII cells. 24-36 hrs
after transfection, the cells were labeled with a biotinylated anti-IL-lRI antibody and then
stained with streptoavidin-PE. Transfected cells with pshIL-lRI-EGFP (EGFP positive
cells) showed a reduced level of IL-lRI (MFI: 53.32 ± 7.38), while the cells that were
transfected with pshGAPDH-EGFP showed a higher level of IL-lRI (MFI: 162.84 ±
17.20). This value is similar to that of the untransfected cells (MFI: 171.68 ± 7.54 and
126.84 ± 6.40) (Fig. 2). This result demonstrated that pshIL-lRI reduced endogenous IL
lRI in transfected cells. From this experiment we chose one pshIL-lR for the rest of the
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experiment.
Reduction of IL-lRI mRNA in the transfected cells with pshIL-lRI-EGFP
To sort the transfected cells with a plasmid, we transfected LEII cells with pshIL-lRI
EGFP. 24-36 hours after transfection of the plasmid, we sorted the EGFP positive cells,
and then performed RT-PCR. The pshIL-lRI-EGFP positive cells showed reduced IL
lRI mRNA compared to· the control pshGAPDH-EGFP positive cells (Fig. 3)

Inhibition of angiogenesis induced by IL-la using pshIL-lRI in eyes
Before we start in vivo experiment, we determined how much plasmid DNA should
be injected. For this purpose, we injected pEGFP 0.5, 1, 2, 4, or 8µg per 2µ1
intrastromally, and found that injection with 1-4µg/2µ1 induced higher transfection. In
addition, we investigated how long transfected pEGFP is expressed. Single injection of
2µg/2µ1 of EGFP into stromal cells induced high expression up to day 3. At day 4,
signals were decreased, but they were detected up to day 8 and 9. In this study, we
injected 2µg/2µ1 of psiIL-lRI or psiGFP.
One day after the intrastromal injection of pshIL-lRI or pshGFP, a pellet containing
IL-la was implanted. Four days after implantation, angiogenesis was observed. The
pshIL-lRI injected eyes showed reduced angiogenesis compared to the pshGFP-injected
eyes (Fig. 4). The angiogenic area of the eyes injected with pshIL-lRI was 1.34 ± 0.39
2

mm ,

and the eyes injected with pshGFP had an angiogenic area of 0.54 ± 0.22 mm2 (Fig.

5). These results indicated that pshIL-lRI can reduce angiogenesis caused by IL-la in
mouse eyes.
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Intrastromal injection of pshIL-lRI reduced mVEGF production induced by IL-la
treatment in eyes

To investigate whether the reduction of angiogenesis in the eyes injected with pshll..
lRI was mediated by inhibition of mVEGF production, we measured the VEGF protein
level from the plasmid-injected eyes. Eyes injected with pshll..-lRI showed a highly
reduced VEGF production compared to the pshGFP injected control eyes (142.50± ±
51.19 pg/eye vs 661.00 ± 199.57 pg/eye) (Table 1). This result indicated that reduced
angiogenesis resulted from reduced VEGF production, and confirmed that the
interruption of IL-1 and IL-lRI can reduce VEGF production and angiogenesis.
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Discussion
Previously it was proposed that IL-1 production after ocular infection of HSV-1
induces IL-6 and VEGF, which causes angiogenesis and HSK (4). The IL-lRa Tg mice,
in which IL-1 and IL-lRJ interaction is interrupted, showed reduced IL-6, VEGF, and its
receptor VEGFR-2 after HSV-1 infection. It was also reported that IL-1 is required for
both angiogenesis and tumor invasiveness using IL-lP or IL-la knockout mice (18). A
different study showed that IL-la induces angiogenesis in vivo through the VEGF
receptor pathway, possibly by inducing VEGF synthesis (19). These results suggest that
the inhibition of IL-1 and IL-lR interaction might be useful as a therapeutic strategy to
reduce angiogenesis.
There are several possible strategies to reduce the interaction between IL-1 and IL-1
receptor. Treatment of recombinant IL-lRa is the most popular because it binds to the IL1 receptor with a high affinity and prevents the binding of IL-1 to its receptor via classic
competitive receptor antagonism (20). In addition, the IL-lRI antibody, antibodies to the
IL-1 receptor accessory protein, and anti-IL-1 neutralizing antibodies can also be used to
reduce IL-1 activity.
In this study, we investigated whether IL-1 activity could be reduced using RNAi
technology. Our results demonstrated that pshIL-lRI transfected cells produced a lower
level of IL-lRI at the mRNA and protein levels (Fig. 2, and Fig.3). Moreover,
intrastromal injection of pshIL-lRI reduced the angiogenesis and VEGF production
caused by IL-la protein in mouse eyes (Fig. 4, Fig. 5, and Table 1). Originally, we tried
to induce IL-la production and angiogenesis by HSV-1 infection in eyes. However,
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intrastromally-injected eyes with plasmid DNA are not well infected, so we implanted
pellets containing IL-la protein to trigger IL-la and its receptor interaction, and
angiogenesis. Although the angiogenesis is not induced by HSV-1 infection, our results
showed that the potential of shRNA against IL-lRI to be used for therapeutic purposes.
Recently, another mechanism by which IL-1� induces angiogenesis was proposed.
Cox-2 overexpression increased the expression of angiogenic factors, such as VEGF, and
bFGF and the cox-2 inhibitor significantly reduced VEGF and bFGF production as well
as angiogenesis (21, 22). Another experiment showed that IL-1� enhanced PEG2 and
TXA2 production and induced angiogenesis (23). Induced production of prostanoids by
IL-1J3 was blocked by the cox-2 selective inhibitors DFU and JTE522 and administration
of the cox-2 inhibitors resulted in the suppression of IL-1� induced angiogenesis in vivo.
Furthermore, TXA2 antagonist and EP4 antagonist inhibited IL-1� induced angiogenesis
in mouse eyes (23). Therefore, treatment of siRNA targeting cox-2, which produces
PGE2 and TXA2 from arachidonic acid, is also an attractive strategy to inhibit
angiogenesis induced by IL-1.
RNAi technology is becoming popular because of the specificity and potency of gene
silencing. In particular, it is widely used to determine unknown gene functions. On the
other hand, some researchers are trying to use this technology for therapeutic purposes.
However, enough cells must be transfected by siRNA or shRNA in order to achieve
enough suppression of unwanted gene expression in vivo. At this time, we do not know
how many cells are transfected by pshIL-lRI, although it was already shown that
intrastromal injection with a plasmid can transfect stromal cells (15, 24). One possible
experiment with which transfection efficiency after intrastromal injection with a plasmid
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could be determined is the confocal image analysis of wholemount cornea (24). After
excision and fixation of pEGFP-injected corneas, they are flatmounted on a slide with
medium containing DAPI and placed for 48hours to allow DAPI to penetrate. Using a
spectral laser scanning confocal microscope with the corresponding laser for DAPI and
EGFP, corneas could be analyzed from z-stacks to see how many cells are transfected in
stromal cells.
Our results showed that intrastromal injection with psiIL-lRI reduced angiogenesis
and VEGF production induced by IL-1 a. Therefore, we assumed that intrastromal
injection transfected enough cells to reduce angiogenesis caused by the IL-1 a. treatment.
Otherwise, shRNA might be spread to neighbor cells after expressed in transfected cells
and inhibit gene expression in untransfected cells as well as transfected cells. In fact,
plant and C._elegans have systemic distribution of siRNA when siRNA is injected locally
(25, 26). In addition, global decrease in HCV protein expression was observed in S 11791
cells, suggesting that either all of the cells were transfected with the siRNA or that RNAi
may have spread from cell to cell (27). For the transfection of a plasmid into stromal cells,
we injected plasmid DNA with pressure to increase transfection, so transient disruption
of cell membrane might be important for the plasmid transfection. However, shRNAs are
much smaller than plasmid DNA. Therefore, it may be possible to be spread (possibly
through gap junction) to next cells after shRNAs are expressed in transfected cells.
Even though we do not know which one is true, it seems that the eye is a suitable
organ to use RNAi technology for in vivo experiments because we and other researchers
have shown that the injection of siRNAs into eyes may inhibit their target gene
expression as well as reduce symptoms (28-30). Previous in vivo experiments targeting
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eyes used slightly different delivery method and different types of dsRNA. Nakamura et
al. injected synthetic siRNA using subconjunctival injection. In other experiments,
subretinal injection or in vivo eletroporation were used to transfect retina with adenoviral
shRNA or plasmid-based shRNA. In our study, we used intrastromal injection with
plasmid-based shRNA.
Each type of dsRNA has its advantages and disadvantages. Synthetic siRNAs are
more convenient and have a higher transfection efficiency, but they are more expensive
and less stable. Virus-mediated shRNAs have a high transfection efficiency and are stable,
but viral infection causes inflammation. On the other hand, plasmid-based shRNAs are
stable, which makes shRNAs active for longer than siRNAs, inexpensive and.non-toxic,
but their transfection efficiency is lower than other dsRNAs. Therefore, the choice of
delivery system and dsRNA depends on the purpose of the experiment. In this study, we
transfected plasmid-based shRNA using intrastromal injection to inhibit the target gene in
stromal cells for longer without causing any inflammation.
Although RNAi technology has limited use in vivo because of delivery problems, our
study shows that RNAi technology may be an attractive strategy when used in mouse
corneas to study corneal biology as well as corneal disease.
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Fig. 1 Plasmid constructs 2.
A. psha-lRI expresses shRNA against a-1 receptor type l(a-lRI)
B. psha-lRI-EGFP expresses shRNA against a-RI and EGFP bicistronically
Sense: sense sequence, Antisense: antisense sequence,
Term.: RNA polymerase III transcription termination sequence,
CMV: CMV promoter, Poly A: poly A sequence
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Fig. 1
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Fig. 2 Inhibition of endogenous IL-lR I protein.
24-36hr after transfection of pshGAPDH (B) or pshIL-lRI (C), cells are harvested
and IL-lRI was stained
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Fig. 3 Inhibiton of endogenous mRNA of IL-lR I.
After sorting of EGFP positive cells (lane 1: pshVEGF-EGFP+, lane 2:
pshIL-lRI-EGFP+), tatal RNA was isolated and RT-PCR was performed.
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Fig. 4 Reduction of angiogenesis induced by IL-la protein by pshIL-lRI.
Intrastromal injection of pshIL-lRI reduced angiogenesis induced by
IL-1a protein. pshGFP was used as a control plasmid.
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A. pshGFP

Fig. 4
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Fig. 5 Angiogenic area at day 4 after implantation of pellet containing IL-1 a
following pshGFP or pshIL- lRI injection.
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* p< 0.01

Table 1. Measurement of the amount oflL-lRI in cornea
using ELISA

pshIL-lRI

pshGFP
VEGF
pg/ eye

142.5± 50.19 *

661.0±199.57

* p <0.03
4 day after implantation of pellet containing IL-1 a protein
following pshGFP or pshVEGF injection, ELISA was performed.
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Concluding remarks
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The aim of our investigations was to exploit the novel approach of shRNA to control
ocular angiogenesis in vivo. Previous experiments demonstrated that angiogenesis in the
cornea is a critical step in HSK, which is caused by ocular infection with HSV-1.
Although the mechanisms of angiogenesis induced by ocular infection of HSV-1 are
unclear, it was shown that bio-active CpG motifs in HSV-1 DNA could contribute to
angiogenesis in the eyes, and the angiogenesis was mediated by VEGF production. From
additional experiments, it was demonstrated that treatment of the anti-mVEGF antibody
prevents CpG induced angiogenesis in mouse eyes. Thus, these results indicate that
mVEGF is a critical factor for angiogenesis caused by CpG motif in mouse eyes, and
mVEGF might be a good target molecule to reduce angiogenesis and HSK severity.
From different experiments, another mechanism of angiogenesis induced by ocular
infection of HSV-1 has been proposed. The experiments showed that ocular infection of
HSV-1 induced IL-1 and IL-6, and the increased expression of the cytokines stimulated
angiogenesis through up-regulation of mVEGF. These results indicated that cytokine
production caused by ocular infection of HSV-1 is a main reason of production of
mVEGF and induction of angiogenesis. This result was confirmed by the experiments
using IL-1 receptor antagonist (IL-lRa) transgenic mice. IL-lRa binds to the IL-1
receptor type I without transmitting activation signal, so it inhibits IL-1 activity. The
ILlRa transgenic mice showed reduced HSK severity and angiogenesis compared to wild
type mice when their eyes are infected with HSV-1. This result indicates that inhibition
of the interaction between the IL-1 and IL-1 receptor can reduce HSK severity and
angiogenesis, and IL-1 or IL-1 receptor may be good candidate molecules to be targeted.
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From these previous experiments, we hypothesized that IL-1 and mVEGF are key
molecules for angiogenesis caused by ocular infection of HSV-1 in mouse eyes, and
investigated whether inhibitions of mVEGF and IL-1 receptor gene expressions using
RNAi technology could reduce angiogenesis in mouse eyes. RNAi is a sequence specific
gene silencing phenomenon by introduction of dsRNA. There are a few different dsRNA
inducing RNAi. In this study we used plasmid based- shRNA to inhibit target gene
expression because it is effective for longer than siRNA (this feature is required for our
experiments because we observed eyes at day 5 after injection.), inexpensive, and non
toxic in eyes.
In vitro experiments showed that the transfected cells with a plasmid DNA expressing

mVEGF shRNA or IL-lRI shRNA reduced exogenous and endogenous target gene
expressions. For these experiments, we constructed plasmid expressing EGFP and
shRNA bicistronically to identify transfected cells. The transfected cells, which are EGFP
positive, were obtained by FACS sorting and were used to detect mRNA levels by RT
PCR or real time PCR. To detect protein level flow cytometry was performed and the
results showed that EGFP positive cells reduced production of target proteins.
After confirmation of the effectiveness of the plasmid based-shRNA, we investigated
whether intrastromal injection with the plasmid could inhibit angiogenesis caused by
CpG motifs or IL-la. The results showed that either plasmid expressing mVEGF shRNA
or IL-lRI shRNA reduced angiogenic area and mVEGF production. These results imply
that RNAi technology can be used in mouse eyes and help to understand corneal biology
and to treat corneal disease induced by unwanted gene expression.
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Recently, another mechanism by which IL-1 � induces angiogenesis was proposed in
eyes. The experiments showed that treatment of IL-1� increased cox-2 production, and
the cox-2 production induced angiogenic factors, such as VEGF and bFGF. In addition,
treatment of cox-2 inhibitor reduced VEGF and bFGF production as well as angiogenesis.
Therefore, it will be interesting to determine whether angiogenesis can be decreased after
targeting of cox-2 mRNA using RNAi technology and to compare the results with those
from the experiments with shRNA against IL-1 receptor.
RNAi technology requires sufficient transfection. At this point we do not know how
many cells are transfected after intrastromal injection with plasmid. In the future, this
question should be solved. One possible experiment to solve the question might be
confocal image analysis of wholemount cornea which is injected with a plasmid
expressing EGFP.
We and other researchers showed that RNAi is induced in mouse eyes, although we
do not know how many cells are transfected. Therefore, it seems that the injection
delivered plasmid into enough number of cells to induce RNAi. Otherwise, expressed
shRNA in transfected cells might be spread to neighbor cells and induce RNAi in un
transfected cells, as well as to transfected cells. It is very important to know how many
cells could be transfected with siRNA or shRNA in vivo, and how many cells should be
transfected in order to see physiological effects in vivo. Another important issue in RNAi
technology is off-target effect. Some researchers reported that siRNAs degraded, not only
target mRNAs, but also other mRNAs. Now, we do not know why off-target effects
occur. We need to know about RNAi machinery more in detail to solve the problems.
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RNAi phenomenon was discovered in 1998, and RNAi was started to use in
mammalian- cells in 2002. Although this technology has very short history, application of
this technique spread very fast especially for the in vitro experiments to determine
unknown gene function. Recently, siRNA libraries were developed to screen many genes
at a same time. Therefore, this technology will help us to understand many unknown gene
functions. RNAi also has potential as a therapeutic strategy because of its specificity and
potency. However, there are many questions including delivery systems to be solved
before this technology can be used for clinical purposes. Although there are some
limitations in RNAi-based therapies, significant work is ongoing to solve the problems.
Even though analyzing gene functions using RNAi already impacted many biological
sciences, better understanding of the nature of siRNAs and RNAi mechanisms will make
this technology more useful.
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